NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company specializing in broad-spectrum antivirals, announced a securities purchase agreement with a single institutional investor for a registered direct offering. The offering is expected to generate gross proceeds of approximately $2 million through the sale of 1,333,334 common shares or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants carry an exercise price of $1.75 per share and a three-year term. The closing is expected on or about May 18, 2026, subject to customary conditions.
This capital raise comes as NanoViricides advances its lead drug candidate, NV-387, which has received Orphan Drug Designation (ODD) from the U.S. FDA Office of Orphan Products Development. The designation could provide seven years of market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. NV-387 is described as a revolutionary antiviral designed to be offered at a patient's first visit for any respiratory viral illness. The drug has shown high effectiveness in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.
The company's technology is based on host-mimetic nanomedicine, which targets viruses and their variants in a way that they cannot escape. This approach positions NanoViricides as a potential leader in the antiviral space, addressing a critical need for broad-spectrum treatments that remain effective against emerging viral threats. The $2 million offering will likely support ongoing clinical trials and further development of NV-387.
Investors can find the latest news and updates regarding NanoViricides on the company's newsroom at https://ibn.fm/NNVC. The full press release detailing the offering is available at https://ibn.fm/Z8Etj.
The offering underscores the continued interest in antiviral therapeutics, particularly those with broad-spectrum potential. For business leaders and technology investors, NanoViricides represents a case study in nanomedicine innovation and its application to infectious diseases. The success of NV-387 could reshape how respiratory viral illnesses are treated, reducing the burden on healthcare systems and providing a first-line defense against future pandemics.
While the company faces the usual risks of clinical-stage biotech firms, including regulatory hurdles and trial outcomes, the ODD status and positive animal model data provide a foundation for cautious optimism. The $2 million raise, though modest, will help bridge the company to key milestones.
